Suggested Remit: To appraise the clinical and cost effectiveness of zanubrutinib within its marketing authorisation for treating Waldenström’s macroglobulinaemia.
Status
|
In progress
|
Decision
|
Selected
|
Process |
STA 2018
|
ID number |
1427
|
Provisional Schedule
Expected publication |
17 August 2022 |
Project Team
Project lead |
Thomas Feist |
Email enquiries
External Assessment Group |
Kleijnen Systematic Reviews Ltd |
Stakeholders
Companies sponsors |
BeiGene |
Others |
Department of Health and Social Care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Blood Cancer UK |
|
Lymphoma Action |
|
WMUK |
Professional groups |
Association of Cancer Physicians |
|
Cancer Research UK |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Comparator companies |
Janssen-Cilag |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare Products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |
Date
|
Update
|
07 June 2022
|
Committee meeting: 2 |
06 May 2022 - 26 May 2022
|
Draft guidance |
12 April 2022
|
Committee meeting: 1 |
09 December 2021
|
The appraisal timelines have now been updated and the first appraisal committee meeting is now scheduled to take place on 12 April 2022. |
24 June 2021
|
NICE have taken the decision to pause this appraisal due to operational reasons, timelines are currently to be confirmed. |
15 February 2021
|
The timelines for this appraisal have been revised and the first appraisal committee meeting is now scheduled to take place on 7 September 2021. This is to allow the company to address the decision problem in the final scope in its submission. |
27 October 2020
|
Invitation to participate |
23 July 2020 - 20 August 2020
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
31 July 2017
|
In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual